Comparative Pharmacology
Head-to-head clinical analysis: QDOLO versus TAPENTADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QDOLO versus TAPENTADOL.
QDOLO vs TAPENTADOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
None Documented
None Documented
Clinical Note
moderateTapentadol + Torasemide
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide."
Clinical Note
moderateTapentadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid."
Clinical Note
moderateTapentadol + Furosemide
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide."
Clinical Note
moderateTapentadol + Bumetanide
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Category C
Category A/B
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide."